The report discusses ten23’s continued progress, with multiple international certifications and SBTi target validation, demonstrating its commitment to ambitious climate targets.

Basel, Switzerland, April 2 2025: ten23 health® the human-centric and sustainable strategic contract development, testing and manufacturing organization in the pharmaceutical sector (CDTMO), and partner of choice for the pharmaceutical industry and biotech start-ups, is proud to announce a range of achievements and sustainability certifications.

ten23’s latest Fairstainability impact report for the full year 2024 follows the Voluntary Sustainability Reporting for non-listed SMEs (VSME) disclosure standard to further enhance transparency on the environmental, social and governance (ESG) activities of the company, and provide a holistic and comprehensive view of its sustainability initiatives.
Highlights include:

57% reduction in Scope 1 and 2 GHG emissions by revenue compared to the 2021 baseline (achieving its 2025 goal one year early)

SBTi validation for its science-based climate targets and completion of its double materiality assessments. This marks a significant milestone in the company’s Fairstainability program, which is aligned with global efforts to limit warming to 1.5°C above pre-industrial levels. The SBTi targets include a short-term goal of a 42% reduction in GHG emissions by 2030 (fusing 2023 as the base year) and a net-zero target of reducing Scope 1, 2, and 3 emissions by at least 90% by 2050 or earlier.

Earning the highest certification level (Green) from MyGreen Lab for its Basel development labs, with an outstanding overall score of 88.

An EcoVadis score of 73 in 2025, placing ten23 in the top 3% of companies in the manufacture of pharmaceutical products and pharmaceutical preparations which are rated by EcoVadis.

These achievements are alongside ten23 becoming the first sterile drug product CDMO to achieve B Corp certification, which was announced in August 2024.

“All the actions and achievements in the report together with our focus on collaboration, underscore ten23 health’s unwavering commitment to fostering a culture of sustainability in the Pharma sector. They reflect the organization’s dedication to adopting and innovating eco-friendly practices and reducing the environmental impact of its operations and value chain. These accomplishments also reinforce ten23 health’s commitment to holistic, tangible, science-driven environmental action,” said Alissa Monk, Co-Fairstainability Lead, ten23 health.

As ten23 health celebrates these achievements, it remains steadfast in its mission to create a materially positive impact on society and the environment. These milestones signify the company’s leadership in driving change towards a more sustainable future.

“The SBTi approval and certifications with MyGreen Lab and Ecovadis are significant milestones for ten23 health. They reaffirm our company’s dedication, leadership role and ambition to leave a heartprint in sustainable business in the Pharma and CDMO sector,” commented Hanns-Christian Mahler, CEO of ten23 health.